Adaptation of high-throughput screening in drug discovery-toxicological screening tests

International Journal of Molecular Sciences

Volumn 13, Issue 1, 2012, Pages 427-452

  Szymański, Paweł ^a   Markowicz, Magdalena ^a   Mikiciuk Olasik, Elzbieta ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cellular microarrays; Drug development; High throughput screening (HTS); Toxicity

Indexed keywords

1 NAPHTHALENESULFONIC ACID [4 [(4 AMINO 2 QUINAZOLINYLAMINO)METHYL]CYCLOHEXYLMETHYL]AMIDE; CYTOCHROME P450; DRUG METABOLIZING ENZYME; ION CHANNEL; POTASSIUM CHANNEL; DRUG;

CALCIUM TRANSPORT; CELLULAR STRESS RESPONSE; COMET ASSAY; CYTOTOXICITY TEST; DNA DAMAGE; DNA REPAIR; DRUG DESIGN; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME METABOLISM; GENE EXPRESSION; GENETIC VARIABILITY; GENOTOXICITY; HIGH THROUGHPUT SCREENING; HUMAN; LIGAND BINDING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MEMBRANE POTENTIAL; NONHUMAN; PATCH CLAMP; PROTEIN PROTEIN INTERACTION; REVIEW; RISK ASSESSMENT; SCREENING TEST; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURE ACTIVITY RELATION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; METABOLISM; MUTAGEN TESTING; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STEM CELL;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; ION CHANNELS; MUTAGENICITY TESTS; PHARMACEUTICAL PREPARATIONS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; STEM CELLS;

EID: 84856250240     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms13010427     Document Type: Review

References (123)

1. Martis, E.A.; Radhakrishnan, R.; Badve, R.R. High-throughput screening: The hits and leads of drug discovery-An overview. J. Appl. Pharm. Sci. 2011, 1, 2-10.
2. Armstrong, J.W. A review of high-throughput screening approaches for drug discovery. Am. Biotechnol. Lab. 1999, 17, 26-28.
3. Fernandes, T.G.; Diogo, M.M.; Clark, D.S.; Dordick, J.S.; Cabral, J. High-throughput cellular microarray platforms: Applications in drug discovery, toxicology and stem cell research. Trends Biotechnol. 2009, 27, 342-349.
4. Fara, D.C.; Oprea, T.; Prossnitz, E.R.; Bologa, C.G.; Edwards, B.S.; Sklar, L.A. Integration of virtual and physical screening. Drug Discov. Today 2006, 3, 337-385.
5. Hann, M.; Opera, T.I. Pursuing the leadlikeness concept in pharmaceutical research. Curr. Opin. Chem. Biol. 2004, 8, 255-263.
6. Clark, R.L.; Johnston, B.F.; Mackay, S.P.; Breslin, C.J.; Robertson, M.; Harley, A.L. The drug discovery portal: A resource to enhance drug discovery from Akademia. Drug Discov. Today 2010, 15, 679-683.
7. Mayr, L.M.; Fuerst, P. The future of high-throughput screening. J. Biomol. Screen. 2008, 13, 443-448.
8. Brandish, P.E.; Chiu, C.S.; Schneeweis, J.; Brandon, N.J.; Leech, C.L.; Kornienko, O. A cell-based ultra-high-throughput screening assay for identifying inhibitors of D-amino acid oxidase. J. Biomol. Screen. 2006, 11, 481-487.
9. Kasibhatla, S.; Gourdeau, H.; Meerovitch, K.; Drewe, J.; Reddy, S.; Qiu, L.; Zhang, H.; Bergeron, F.; Bouffard, D.; Yang, Q.; et al. Discovery and mechanism of action of novel series of apoptosis inducers with potential vascular targeting activity. Mol. Cancer Ther. 2004, 3, 1365-1373.
10. Mueller, H.; Kassack, M.; Wiese, M. Comparison of the usefulness of MTT, ATP and calcein assays to predict the potency of cytotoxic agents in various human cancer cell lines. J. Biomol. Screen. 2004, 9, 506-515.
11. Chen, D.S.; Davis, M.M. Molecular and functional analysis using live cell microarrays. Curr. Opin. Chem. Biol. 2006, 10, 28-34.
12. Soen, Y.; Chen, D.S.; Kraft, D.L.; Davis, M.M.; Brown, P.O. Detection and characterization of cellular immune responses using peptide-MHC microarrays. PLoS Biol. 2003, 1, doi:10.1371/journal.pbio.0000065.
13. Orner, B.P.; Derda, R.; Lewis, R.L.; Thomson, J.A.; Kiessling, L.L. Arrays for the combinatorial exploration of cell adhesion. J. Am. Chem. Soc. 2004, 126, 10808-10809.
14. How, S.E.; Yingyongnarongkul, B.; Fara, M.A.; Diaz-Mochon, J.J.; Mittoo, S. Polyplexes and lipoplexes for mammalian gene delivery: From traditional to microarray screening. Comb. Chem. High Throughput Screen. 2004, 7, 423-430.
15. Hubbell, J.A. Biomaterials science and high-throughput screening. Nat. Biotechnol. 2004, 22, 828-829.
16. Jang, J.-H.; Schaffer, D.V. Microarraying the cellular microenvironment. Mol. Syst. Biol. 2006, 2, doi:10.1038/msb4100079.
17. Figallo, E.; Cannizzaro, C.; Gerecht, S.; Burdick, J.A.; Langer, R.; Elvassore, N. Micro-bioreactor array for controlling cellular microenvironments. Lab. Chip. 2007, 7, 710-719.
18. Ruiz, A.; Buzanska, L.; Gilliland, D.; Rauscher, H.; Sirghi, L.; Sobanski, T.; Zychowicz, M.; Ceriotti, L.; Bretagnol, F.; Coecke, S.; et al. Micro-stamped surfaces for the patterned growth of neural stem cells. Biomaterials 2008, 29, 4766-4774.
19. Lee, M.Y.; Kumar, R.A.; Sukumaran, S.M.; Hogg, M.G.; Clark, D.S.; Dordick, J.S. Three-dimensional cellular microarrays for highthroughput toxicology assays. Proc. Natl. Acad. Sci. USA 2008, 105, 59-63.
20. Lee, M.Y.; Park, C.B.; Dordick, J.S.; Clark, D.S. Metabolizing enzyme toxicology assay chip (MetaChip) for high-throughput microscale toxicity analyses. Proc. Natl. Acad. Sci. USA 2005, 102, 983-987.
21. Khetani, S.R.; Bhatia, S.N. Microscale culture of human liver cells for drug development. Nat. Biotechnol. 2008, 26, 120-126.
22. Bailey, S.N.; Sabatini, D.M.; Stockwell, B.R. Microarrays of small molecules embedded in biodegradable polymers for use in mammalian cell-based screens. Proc. Natl. Acad. Sci. USA 2004, 101, 16144-16149.
23. Koh, H.L.; Yau, W.P.; Ong, P.S.; Hegde, A. Current trends in modern pharmaceutical analysis for drug discovery. Drug Discov. Today 2003, 8, 889-897.
24. Shukla, S.; Huang, R.; Austin, C.P.; Xia, M. Foundation review: The future of toxicity testing: A focus on in vitro methods using a quantitative high-throughput screening platform. Drug Discov. Today 2010, 15, 997-1007.
25. Cotgreave, I.A. How can stem cell technologies be applied to replace animal use in toxicity testing? Toxicol. Lett. 2011, 205 (Suppl.), S29.
26. Valerio, L.G. In silico toxicology for the pharmaceutical science. Toxicol. Appl. Pharmacol. 2009, 241, 356-370.
27. Hartung, T. From alternative methods to a new toxicology. Eur. J. Pharm. Biopharm. 2011, 77, 338-349.
28. Koop, R. Combinatorial biomarkers: From early toxicology assays to patient population profiling. Drug Discov. Today 2005, 10, 781-788.
29. Barratt, M.D.; Rodford, R.A. The computational prediction of toxicity. Curr. Opin. Chem. Biol. 2001, 5, 383-388.
30. Hansch, C. The expanding role of quantitative structure-activity relationships (QSAR) in toxicology. Toxicol. Lett. 1995, 79, 45-53.
31. Contrera, J.F.; Matthews, E.J.; Benz, D.R. Predicting the carcinogenic potential of pharmaceuticals in rodents using molecular structural similarity and E-state indices. Regul. Toxicol. Pharmacol. 2003, 38, 243-259.
32. Lee, S.K.; Lee, I.H.; Kim, H.J.; Chang, G.S.; Chung, J.E.; No, K.T. The PreADME Approach: Web-Based Program for Rapid Prediction of Physico-Chemical, Drug Absorption and Drug-Like Properties; Blackwell Publishing: Boston, MA, USA, 2003; pp: 418-420.
33. Klopman, G. Multicase 1. A hierarchical computer automated structure evaluation program. Quant. Struct. 1992, 11, 176-184.
34. Matthews, E.J.; Contrera, J.F. A new highly specific method for predicting the carcinogenic potential of pharmaceuticals in rodents using enhanced MCASE QSAR-ES Software. Regul. Toxicol. Pharmacol. 1998, 28, 242-264.
35. Enslein, K. Computation of developmental toxicity potential by QSTR models in the TOPKAT program. In Advances in Animal Alternatives for Safety and Efficacy Testing; Salem, H., Katz, S.A., Eds.; Taylor & Francis: Abingdon, UK, 1998; pp. 159-167.
36. Helma, C. Lazy structure-activity relationships (lazar) for the prediction of rodent carcinogenicity and Salmonella mutagenicity. Mol. Divers. 2006, 10, 147-158.
37. Johnson, D.E.; Rodgers, A.D.; Sudarsanam, S. Future of computational toxicology: Broad application into human disease and therapeutics. In Computational Toxicology: Risk Assessment for Pharmaceutical and Environmental Chemicals; Ekins, S., Ed.; John Wiley & Sons: Hoboken, NJ, USA, 2007; Chapter 26.
38. Lewis, D.F.V.; Ioannides, C.; Parke, D.V. Validation of a novel molecular orbital approach (COMPACT) for the prospective safety evaluation of chemicals, by comparison with rodent carcinogenicity and the Salmonella mutagenicity data evaluated by the U.S. NCI/NTP. Mutat. Res. 1993, 291, 61-77.
39. Lewis, D.F.V. COMPACT: A structural approach to the modelling of cytochromes P450 and their interactions with xenobiotics. J. Chem. Technol. Biotechnol. 2001, 76, 237-244.
40. Woo, Y.-T.; Laiand, D.Y. OncoLogic: A mechanism-based expert system for predicting the carcinogenic potential of chemicals. In Predictive Toxicology; Hemla, C., Ed.; CRC Press: Boca Raton, FL, USA, 2005; pp. 385-413.
41. Ekins, S. Algorithms for network analysis in systems-ADME/Tox using the MetaCore and MetaDrug platforms. Xenobiotica 2006, 36, 877-901.
42. Debnath, A.K.; Lopez de Compadre, R.L.; Debnath, G.; Shusterman, A.J.; Hansch, C. Structure-activity relationship of mutagenic aromatic and heteroaromatic nitro compounds. Correlation with molecular orbital energies and hydrophobicity. J. Med. Chem. 1991, 34, 786-797.
43. Vedani, A.; Dobler, M.; Lill, M.A. The challenge of predicting drug toxicity in silico. Basic Clin. Pharmacol. Toxicol. 2006, 99, 195-208.
44. Okada, T. Characteristic substructures and properties in chemical carcinogens studied by the cascade model. Bioinformatics 2003, 19, 1208-1215.
45. Judson, P.N. Using Computer Reasoning about Qualitative and Quantitative Information to Predict Metabolism and Toxicity. In Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies; Wiley: Hoboken, NJ, USA, 2006; pp. 183-215.
46. Smithing, M.P.; Darvas, F. HazardExpert. An expert system for predicting chemical toxicity. ACS Symp. Ser. 1992, 484, 191-200.
47. Houck, K.A.; Kavlock, R.J. Understanding mechanisms of toxicity: Insights from drug discovery research. Toxicol. Appl. Pharmacol. 2008, 277, 163-178.
48. Kavlock, R.J.; Ankley, G.; Blancato, J.; Breen, M.; Conolly, R.; Dix, D.; Houck, K.; Hubal, E.; Judson, R.; Rabinowitz, J.; et al. Computational toxicology-A state of the science mini review. Toxicol. Sci. 2008, 103, 14-27.
49. Seidle, T.; Stephens, M.L. Bringing toxicology into the 21st century: A global call to action. Toxicol. in Vitro 2009, 23, 1576-1579.
50. Richard, A.M. Future of toxicology-Predictive toxicology: An expanded view of "chemical toxicity". Chem. Res. Toxicol. 2006, 19, 1257-1262.
51. Lau, Y.Y.; Sapidou, E.; Cui, X.; White, R.E.; Cheng, K.C. Development of a novel in vitro model to predict hepatic clearance using fresh, cryopreserved, and sandwich-cultured hepatocytes. Drug Metab. Dispos. 2002, 30, 1446-1454.
52. Shibata, Y.; Takahashi, H.; Chiba, M.; Ishii, Y. Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: An application of serum incubation method. Drug Metab. Dispos. 2002, 30, 892-896.
53. Bernauer, U.; Glatt, H.; Heinrich-Hirsh, B.; Liu, Y.; Muckel, E.; Vieth, B.; Gundert-Remy, U. Heterologous expression of mouse cytochrome P450 2E1 in V79 cells: Construction and characterization of the cell line and comparison with V79 cell lines stably expressing rat P450 2E1 and human P450 2E1. Altern. Lab. Anim. 2003, 31, 21-30.
54. Crespi, C.L.; Miller, V.P.; Penman, B.W. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal. Biochem. 1997, 248, 188-190.
55. Trubetskoy, O.V.; Gibson, J.R.; Marks, B.D. Highly miniaturized formats for in vitro drug metabolism assays using vivid fluorescent substrates and recombinant human cytochrome P450 enzymes. J. Biomol. Screen. 2005, 10, 56-66.
56. Lee, M.Y.; Park, C.B.; Dordick, J.S.; Clark, D.S. Metabolizing enzyme toxicology assay chip (MetaChip) for high-throughput microscale toxicity analyses. Proc. Natl. Acad. Sci. USA 2005, 102, 983-987.
57. Li, A.P.; Bode, C.; Sakai, Y. A novel in vitro system, the integrated discrete multiple organ cell culture (IdMOC) system, for the evaluation of human drug toxicity: Comparative cytotoxicity of tamoxifen towards normal human cells from five major organs and MCF-7 adenocarcinoma breast cancer cells. Chem. Biol. Interact. 2004, 150, 129-136.
58. Luo, G.; Cunningham, M.; Kim, S.; Burn, T.; Lin, J.; Sinz, M.; Hamilton, G.; Rizzo, C.; Jolley, S.; Gilbert, D.; et al. CYP3A4 induction by drugs: Correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab. Dispos. 2002, 30, 795-804.
59. Cui, X.; Thomas, A.; Han, Y.; Palamanda, J.; Montgomery, D.; White, R.E.; Morrison, R.A.; Cheng, K.C. Quantitative PCR assay for cytochromes P450 2B and 3A induction in rat precision-cut liver slices: Correlation study with induction in vivo. J. Pharmacol. Toxicol. Methods 2005, 53, 215-218.
60. Corona, G.; Toffoli, G. High throughput screening of genetic polymorphisms by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Comb. Chem. High Throughput Screen. 2004, 7, 707-725.
61. Gunaratna, C. Drug metabolism and pharmacokinetics. Curr. Sep. 2000, 19, 17-23.
62. Marks, B.D.; Goossens, T.A.; Braun, H.A.; Ozers, M.S.; Smith, R.S.; Lebakken, C.; Trubetskoy, O.V. High-throughput screening Assays for CYP2B6 Metabolism and Inhibition. AAPS PharmSci 2003, 5, 1-11.
63. Evans, T.J.; Yamamoto, K.N.; Hirota, K.; Takeda, S. Mutant cells defective in DNA repair pathways provide a sensitive high-throughput assay for genotoxicity. DNA Repair 2010, 9, 1292-1298.
64. Kirkland, D.; Aardema, M.; Henderson, L.; Muller, L. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. Mutat. Res. 2005, 584, 251-256.
65. Miller, J.E.; Vlasakova, K.; Glaab, W.E.; Skopek, T.R. A low volume, high-throughput forward mutation assay in Salmonella typhimurium based on fluorouracil resistance. Mutat. Res. 2005, 578, 210-224.
66. Fluckiger-Isler, S.; Baumeister, M.; Braun, K.; Gervais, V.; Hasler-Nguyen, N.; Reimann, R.; van Gompel, J.; Wunderlich, H.G.; Engelhardt, G. Assessment of the performance of the Ames II assay: A collaborative study with 19 coded compounds. Mutat. Res. 2004, 558, 181-197.
67. Lang, P.; Yeow, K.; Nichols, A.; Scheer, A. Cellular imaging in drug discovery. Nat. Rev. Drug Discov. 2006, 5, 343-356.
68. Ritter, D.; Knebel, J. Genotoxicity testing in vitro-Development of a higher throughput analysis method based on the comet assay. Toxicol. in Vitro 2009, 23, 1570-1575.
69. Scrivens, M.; Bhogal, N. The use of human cell line reporter gene-based assays in chemical toxicity testing. Toxicol. in Vitro 2007, 21, 1233-1240.
70. Triggle, D. Voltage-Gated Ion Channels as Drug Targets; John Wiley & Sons: Hoboken, NJ, USA, 2006.
71. Xu, J.; Wang, X.; Ensign, B.; Li, M.; Wu, L.; Guia, A.; Xu, J. Ion-channel assay technologies: Quo vadis? Drug Discov. Today 2001, 6, 1278-1287.
72. Comley, J. Automated patch clamping setting a new standard for early hERG. Drug Discov. World 2005, 6, 62-79.
73. Molokanova, E.; Savchenko, A. Bright future of optical assays for ion channel drug discovery. Drug Discov. Today 2008, 13, 14-22.
74. Mattheakis, L.C.; Savchenko, A. Assay technologies for screening ion channel targets. Curr. Opin. Drug Discov. Devel. 2001, 1, 124-134.
75. Rudiger, R.; Mongillo, M.; Rizzuto, R.; Pozzan, T. Looking forward to seeing calcium. Nat. Rev. Mol. Cell Biol. 2003, 4, 579-586.
76. Finlayson, K.; Turnbull, L.; January, C.T.; Sharkey, J.; Kelly, J.S. [3H]dofetilide binding to HERG transfected membranes: A potential high throughput preclinical screen. Eur. J. Pharmacol. 2001, 430, 147-148.
77. Cheng, C.S.; Alderman, D.; Kwash, J.; Dessaint, J.; Patel, R.; Lescoe, M.K.; Kinrade, M.B.; Yu, W. A high-throughput HERG potassium channel function assay: An old assay with a new look. Drug Dev. Ind. Pharm. 2002, 28, 177-191.
78. Murphy, S.M.; Palmer, M.; Poole, M.F.; Padegimas, L.; Hunady, K.; Danzig, J.; Gill, S.; Gill, R.; Ting, A.; Sherf, B.; et al. Evaluation of functional and binding assays in cells expressing either recombinant or endogenous hERG channel. J. Pharmacol. Toxicol. Methods 2005, 54, 42-55.
79. Giddings, S.J.; Clarke, S.E.; Gibson, G.G. CYP4A1 gene transfection studies and the peroxisome proliferator-activated receptor: Development of a high-throughput assay to detect peroxisome proliferators. Eur. J. Drug Metab. Pharmacokinet. 1997, 22, 315-319.
80. Chin, J.; Adams, A.D.; Bouffard, A.; Green, A.; Lacson, R.G.; Smith, T.; Fischer, P.A.; Menke, J.G.; Sparrow, C.P.; Mitnaul, L.J. Miniaturization of cell-based beta-lactamase-dependent FRET assays to ultra-high throughput formats to identify agonists of human liver X receptors. Assay Drug Dev. Technol. 2003, 1, 777-787.
81. Ozers, M.S.; Ervin, K.M.; Steffen, C.L.; Fronczak, J.A.; Lebakken, C.S.; Carnahan, K.A.; Lowery, R.G.; Burke, T.J. Analysis of liganddependent recruitment of coactivator peptides to estrogen receptor using fluorescence polarization. Mol. Endocrinol. 2005, 19, 25-34.
82. Liu, J.; Knappenberger, K.S.; Kack, H.; Andersson, G.; Nilsson, E.; Dartsch, C.; Scott, C.W. A homogeneous in vitro functional assay for estrogen receptors: Coactivator recruitment. Mol. Endocrinol. 2003, 17, 346-355.
83. Rouleau, N.; Turcotte, S.; Mondou, M.H.; Roby, P.; Bosse, R. Development of a versatile platform for nuclear receptor screening using AlphaScreen. J. Biomol. Screen. 2003, 8, 191-197.
84. Nichols, J.S.; Parks, D.J.; Consler, T.G.; Blanchard, S.G. Development of a scintillation proximity assay for peroxisome proliferator-activated receptor gamma ligand binding domain. Anal. Biochem. 1998, 257, 112-119.
85. Dix, D.J.; Houck, K.A.; Martin, M.T.; Richard, A.M.; Setzer, R.W.; Kavlock, R.J. The ToxCast program for prioritizing toxicity testing of environmental chemicals. Toxicol. Sci. 2007, 95, 5-12.
86. Fliri, A.F.; Loging, W.T.; Thadeio, P.F.; Volkmann, R.A. Biological spectra analysis: Linking biological activity profiles to molecular structure. Proc. Natl. Acad. Sci. USA 2005, 102, 261-266.
87. Rueeger, H.; Gerspacher, M.; Buehlmayer, P.; Rigollier, P.; Yamaguchi, Y.; Schmidlin, T.; Nick, H.; Cricione, L. Discovery and SAR of potent, orally available and brain-penetrable 5,6-dihydro-4H-3-thia-1-aza-benzo[e]azulenand 4,5-dihydro-6-oxa-1-aza-benzo[e]azulenderivatives as neuropeptide Y Y5 receptor antagonists. Bioorg. Med. Chem. Lett. 2004, 14, 2451-2457.
88. Criscione, L. Food intake in freefeeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor. J. Clin. Invest. 1998, 102, 2136-2145.
89. Della Zuana, O.; Sadlo, M.; Germain, M.; Félétou, M.; Chamorro, S.; Duhault, J.; Boutin, J.A.; Levens, N. Reduced food intake in response to CGP 71683A may be due to mechanisms other than NPY Y5 receptor blockade. Int. J. Obes. 2001, 25, 84-94.
90. Rausch, O. High content cellular screening. Curr. Opin. Chem. Biol. 2006, 10, 316-320.
91. Giuliano, K.A.; DeBiasio, R.L.; Dunlay, R.T.; Gough, A.; Volosky, J.M.; Zock, J.; Pavlakis, G.N.; Taylor, D.L. High-content screening: A new approach to easing key bottlenecks in the drug discovery process. J. Biomol. Screen. 1997, 2, 249-259.
92. O'Brien, P.J.; Irwin, W.; Diaz, D.; Howard-Cofield, E.; Krejsa, C.M.; Slaughter, M.R.; Gao, B.; Kaludercic, N.; Angeline, A.; Bernardi, P.; et al. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch. Toxicol. 2006, 80, 580-604.
93. Shoemaker, R.H.; Scudiero, D.A.; Melillo, G.; Currens, M.J.; Monks, A.P.; Rabow, A.A.; Covell, D.G.; Sausville, E.A. Application of highthroughput, molecular-targeted screening to anticancer drug discovery. Curr. Top. Med. Chem. 2002, 2, 229-246.
94. Glover, C.J.; Rabow, A.A.; Isgor, Y.G.; Shoemaker, R.H.; Covell, D.G. Data mining of NCI's anticancer screening database reveals mitochondrial complex I inhibitors cytotoxic to leukemia cell lines. Biochem. Pharmacol. 2007, 73, 331-340.
95. Berg, E.L.; Kunkel, E.J.; Hytopoulos, E.; Plavec, I. Characterization of compound mechanisms and secondary activities by BioMAP analysis. J. Pharmacol. Toxicol. Methods 2006, 53, 67-74.
96. MacDonald, M.L.; Lamerdin, J.; Owens, S.; Keon, B.H.; Bilter, G.K.; Shang, Z.; Huang, Z.; Yu, H.; Dias, J.; Minami, T.; et al. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat. Chem. Biol. 2006, 2, 329-337.
97. Kirstein, S.L.; Atienza, J.M.; Xi, B.; Zhu, J.; Yu, N.; Wang, X.; Xu, X.; Abassi, Y.A. Live cell quality control and utility of real-time cell electronic sensing for assay development. Assay Drug Dev. Technol. 2006, 4, 545-553.
98. Perrimon, N.; Ni, J.Q.; Perkins, L. In vivo RNAi: Today and tomorrow. Cold Spring Harb. Perspect. Biol. 2010, 2, 1-11.
99. Anderson, G.L.; Cole, R.D.; Williams, P.L. Assessing behavioral toxicity with Caenorhabditis elegans. Environ. Toxicol. Chem. 2004, 23, 1235-1240.
100. Zhang, C.; Willett, C.; Fremgen, T. Zebrafish: An animal model for toxicological studies. In Current Protocols in Toxicology; John Wiley & Sons: Hoboken, NJ, USA, 2003; Unit 1.7.
101. Fairn, G.D.; MacDonald, K.; McMaster, C.R. A chemogenomic screen in Saccharomyces cerevisiae uncovers a primary role for the mitochondria in farnesol toxicity and its regulation by the Pkc1 pathway. J. Biol. Chem. 2007, 282, 4868-4874.
102. Parsons, A.B.; Lopez, A.; Givoni, I.E.; Williams, D.E.; Gray, C.A.; Porter, J.; Chua, G.; Sopko, R.; Brost, R.L.; Ho, C.H.; et al. Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast. Cell 2006, 126, 611-625.
103. Lee, M.Y.; Park, C.B.; Dordick, J.S.; Clark, D.S. Metabolizing enzyme toxicology assay chip (MetaChip) for high-throughput microscale toxicity analyses. Proc. Natl. Acad. Sci. USA 2005, 102, 983-987.
104. Liao, V.H.; Yu, C.W. Caenorhabditis elegans gcs-1 confers resistance to arsenic-induced oxidative stress. Biometals 2005, 18, 519-528.
105. Pulak, R. Techniques for analysis, sorting, and dispensing of C. elegans on the COPAS flow-sorting system. Methods Mol. Biol. 2006, 351, 275-286.
106. Haendel, M.A.; Tilton, F.; Bailey, G.S.; Tanguay, R.L. Developmental toxicity of the dithiocarbamate pesticide sodium metam in zebrafish. Toxicol. Sci. 2005, 81, 390-400.
107. Parng, C.; Roy, N.M.; Ton, C.; Lin, Y.; McGrath, P. Neurotoxicity assessment using zebrafish. J. Pharmacol. Toxicol. Methods 2007, 55, 103-112.
108. Nasevicius, A.; Ekker, S.C. The zebrafish as a novel system for functional genomics and therapeutic development applications. Curr. Opin. Mol. Ther. 2001, 3, 224-228.
109. Baranowski, T.; Hesley, J.; Cromwell, E.; Gedraitis, P.R. Novel imaging and analysis of zebrafish for high throughput screening. J. Pharmacol. Toxicol. Methods 2011, 64, doi:10.1016/j.vascn.2011.03.185.
110. Bhambure, R.; Kumar, K.; Rathore, A.S. High-throughput process development for biopharmaceutical drug substances. Trends Biotechnol. 2011, 29, 127-135.
111. Mahadevan, B.; Snyder, R.D.; Waters, M.D.; Benz, R.D.; Kemper, R.A.; Tice, R.R.; Richard, A.M. Genetic toxicology in the 21st century: Reflections and future directions. Environ. Mol. Mutagen. 2011, 52, 339-354.
112. Gribbon, P.; Sewing, A. High-throughput drug discovery: What can we expect from HTS? Drug Discov. Today 2005, 10, 17-22.
113. Kumar, R.A.; Clark, D.S. High-throughput screening of biocatalytic activity: Applications in drug discovery. Curr. Opin. Chem. Biol. 2006, 10, 162-168.
114. Wang, T.; Zeng, L.; Strader, T.; Burton, L.; Kassel, D.B. A new ultra-high throughput method for characterizing combinatorial libraries incorporating a multiple probe autosampler coupled with flow injection mass spectrometry analysis. Rapid Commun. Mass Spectrom. 1998, 12, 1123-1129.
115. Tutko, D.C.; Henry, K.D.; Winger, B.E.; Stout, H.; Hemling, M. Sequential mass spectrometry and MSn analysis of combinatorial libraries by using automated matrix-assisted laser desorption/ionization Fourier transform mass spectrometry. Rapid Commun. Mass Spectrom. 1998, 12, 335-338.
116. Hajduk, P.J.; Burns, D.J. Integration of NMR and highthroughput screening. Comb. Chem. High Throughput Screen. 2002, 5, 613-621.
117. Ermer, J.; Vogel, M. Applications of hyphenated LC-MS techniques in pharmaceutical analysis. Biomed. Chromatogr. 2000, 14, 373-383.
118. Hughes, I.; Hunter, D. Techniques for analysis and purification in high-throughput chemistry. Curr. Opin. Chem. Biol. 2001, 5, 243-247.
119. Kyranos, J.N. High-throughput techniques for compound characterization and purification. Curr. Opin. Drug Discov. Dev. 2001, 4, 719-772.
120. Lyne, P.D. Structure-based virtual screening: An overview. Drug Discov. Today 2002, 7, 1047-1055.
121. Weber, L. Multi-component reactions and evolutionary chemistry. Drug Discov. Today 2002, 7, 143-147.
122. Seifert, M.; Wolf, K.; Witt, D. Virtual high-throughput in silico screening. Biosilico 2003, 1, 143-149.
123. Ekins, S.; Shimada, J.; Chang, C. Application of data mining approaches to drug delivery. Adv. Drug Deliv. Rev. 2006, 58, 1409-1430.